75000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 75010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 75020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 75030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 75040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 75050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 75060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 75070 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Nature of the Business link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Product Revenue, Net link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Stock Option and Grant Plan link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Asset Acquisitions and Collaboration Agreements link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Segments link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Product Revenue, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Stock Option and Grant Plan (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Segments (Tables) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Nature of the Business - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Marketable Securities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Marketable Securities - Schedule of Marketable Securities Classified as Available-for-sale (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Marketable Securities - Schedule of Marketable Securities Classified as Available-for-sale (Details) 2 link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Inventories - Summary of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Inventories - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Stock Option and Grant Plan - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Stock Option and Grant Plan - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Stock Option and Grant Plan - Summary of Restricted Stock Unit Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Stock Option and Grant Plan - Summary of Performance-Based Restricted Stock Unit Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Stock Option and Grant Plan - Summary of Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Stock Option and Grant Plan - Summary of Unrecognized Stock-Based Compensation Expense and Weighted-Average Recognition Period (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Stockholders' Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from the Calculation of Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Asset Acquisitions and Collaboration Agreements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Segments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Segments - Schedule of Segment Revenue and Expenses to Consolidated Net Loss (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Segments - Schedule of Segment Revenue and Expenses to Consolidated Net Loss (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Subsequent Events - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Vested Avexitide [Member] Avexitide. Avexitide Non Rule 10b51 Arr Modified [Flag] Non Rule 10b51 Arr Modified. Non-Rule 10b5-1 Arrangement Modified Schedule of Nonvested Performance-Based Units Activity [Table Text Block] Summary of Performance-Based Restricted Stock Unit Activity Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Preferred stock shares issued Preferred Stock, Shares Issued Preferred Stock, Shares Issued, Total Increase (Decrease) in Accounts Payable, Total Increase (Decrease) in Accounts Payable Accounts payable Research and Development Expense [Abstract] Direct research and development expenses by program: Equity [Abstract] Entity Current Reporting Status Entity Current Reporting Status Charge For In Process Research And Development Milestones Charge for in process research and development milestones. Charge for In-Process Research and Development ("IPR&D") milestones Operating Expenses [Abstract] Operating expenses: Less : Fair Value, Inputs, Level 2 [Member] Level 2 Performance-Based Restricted Stock Units [Member] Performance-Based Restricted Stock Units. Performance-Based Restricted Stock Units Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common stock authorized Common Stock, Shares Authorized Common stock, shares authorized Product and Service [Axis] Document Fiscal Period Focus Document Fiscal Period Focus Revenue from Contract with Customer [Abstract] Entity Shell Company Entity Shell Company Beginning Balance, Shares Ending Balance, Shares Preferred Shares Outstanding Temporary Equity, Shares Outstanding Temporary equity, shares outstanding Other Accrued Liabilities, Current Other accrued expenses Short-term Investments Short-Term Investments [Member] Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalent Cash and cash equivalents Inventory current and noncurrent. Inventory Current and Noncurrent Total inventories Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Number of common stock for sale in underwritten public offering Common Stock, Shares, Issued, Total Common Stock, Shares, Issued Common stock, shares, issued Asset Class [Domain] Asset Class Statement [Table] Statement [Table] Restricted Cash, Noncurrent Restricted cash Weighted average grant-date fair value of options granted during the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Summary of unrecognized stock-based compensation expense and weighted-average recognition period. Summary Of Unrecognized Stock Based Compensation Expense And Weighted Average Recognition Period Table [Text Block] Summary of Unrecognized Stock-Based Compensation Expense and Weighted-Average Recognition Period Proceeds from Debt, Net of Issuance Costs Proceeds from financings, net of issuance costs Statement [Line Items] Statement [Line Items] Entity Filer Category Entity Filer Category Conversion of preferred stock into common stock upon initial public offering Conversion of preferred stock into common stock upon initial public offering Temporary equity values conversion of preferred stock into common stock upon initial public offering. Temporary Equity Values Conversion Of Preferred Stock Into Common Stock Upon Initial Public Offering Temporary Equity Conversion of preferred stock into common stock upon initial public offering Liabilities and Equity Total liabilities and stockholders' equity Payables and Accruals [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted-Average Exercise Price, Options exercisable Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents Subsequent Event [Line Items] Other Noncash Income (Expense) Other Noncash Income (Expense), Total Other non-cash items Share-based compensation arrangement by share-based payment award options unvested intrinsic value. Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Intrinsic Value Aggregate Intrinsic Value, Options unvested Options to Purchase Common Stock Stock Options Interest income Investment Income, Interest Interest income Finished goods Inventory, Finished Goods, Gross Underlying Asset Class [Domain] Underlying Asset Class Schedule of Inventory, Current [Table Text Block] Summary of Inventories Additional Paid in Capital, Common Stock, Ending Balance Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock Additional paid-in capital Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Number of Options, Granted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Summary of the Numerator and Denominators Used in Computation of Earnings Per Share Earnings Per Share, Basic, Total Earnings Per Share, Basic Net loss per share - basic Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation (loss) gain Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Number of Options, Outstanding Number of Options, Outstanding Liabilities, Current Total current liabilities Consolidation Items [Domain] Equity, Attributable to Parent [Abstract] Stockholders' equity: Entity Small Business Entity Small Business Increase (Decrease) in Accrued Liabilities, Total Increase (Decrease) in Accrued Liabilities Accrued expenses Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Nature of Operations [Text Block] Nature of the Business Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Number of Options, Cancelled or forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Aggregate Intrinsic Value, Exercised Aggregate intrinsic value, exercised Commitments and contingencies. Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Cost, Depreciation and Amortization Cost, Depreciation and Amortization, Total Depreciation and amortization expense Share-Based Payment Arrangement [Text Block] Stock Option and Grant Plan Organization, Consolidation and Presentation of Financial Statements [Abstract] Amendment Flag Amendment Flag Product and Service [Domain] Gina M. Mazzariello Gina M. Mazzariello [Member] Gina M. Mazzariello. Inventory Disclosure [Text Block] Inventories Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Entity Address, Postal Zip Code Entity Address, Postal Zip Code Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Net cash used in operating activities Operating lease liabilities Increase (Decrease) in Operating Lease Liability Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description Common Stock [Member] Common Stock Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted-Average Exercise Price, Granted Interest Receivable, Current Accrued interest receivable Debt Securities, Available-for-Sale [Line Items] Schedule Of Available For Sale Securities [Line Items] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type Entity Address, Address Line One Entity Address, Address Line One Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV Earnings Per Share [Abstract] Denominator: Ending Balance Beginning Balance Redeemable convertible preferred stock Temporary Equity, Carrying Amount, Attributable to Parent Carrying Value Investment Type Investment Type [Axis] Operating Lease, Right-of-Use Asset Operating lease right-of-use assets Inventory Disclosure [Abstract] Document Type Document Type Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Entity Central Index Key Entity Central Index Key Personnel-related research and development Personnel Related Research And Development Personnel related research and development. Debt Securities, Available-for-Sale [Table Text Block] Schedule of Marketable Securities Classified as Available-for-sale Asset Acquisition [Table] Investments, Debt and Equity Securities [Abstract] Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Net increase (decrease) in cash, cash equivalents and restricted cash equivalents Subsequent Event Type [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Total excluded common stock equivalents Common Stock, Par or Stated Value Per Share Common stock, stated par value per share Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other comprehensive (loss) income Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted- Average Remaining Contractual Term (in years), Outstanding Debt Securities, Available-for-Sale, Amortized Cost Amortized Cost Basis Debt Securities, Available-for-sale, Total Debt Securities, Available-for-Sale Fair Value Asset Acquisitions And Collaboration Agreements [Text Block] Asset acquisitions and collaboration agreements. Asset Acquisitions and Collaboration Agreements Number of Options, Exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Issuance of common stock upon exercise of stock options, Shares Number of Options, Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Number of Options, Options unvested Performance-Based Restricted Stock Unit Performance Based Restricted Stock Unit [Member] Performance based restricted stock unit. Accrued Liabilities, Current, Total Accrued Liabilities, Current Accrued expenses Cost of Sales Cost of Sales [Member] Current Fiscal Year End Date Current Fiscal Year End Date Document Quarterly Report Document Quarterly Report Series A Redeemable Convertible Preferred Stock Series A redeemable convertible preferred share. Series A Redeemable Convertible Preferred Shares [Member] Series A Redeemable Convertible Preferred Share Entity Address, State or Province Entity Address, State or Province Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of shares, Nonvested Number of shares, Nonvested Conversion of preferred stock into common stock upon initial public offering Conversion of preferred stock into common stock upon initial public offering Stock Issued During Period, Value, Conversion of Convertible Securities Share-based compensation arrangement by share-based payment award options unvested weighted average remaining contractual term. Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Weighted Average Remaining Contractual Term Weighted- Average Remaining Contractual Term (in years), Options unvested Business Combinations and Other Purchase of Business Transactions, Policy [Policy Text Block] Business Combinations and Asset Acquisitions Preferred Stock, Shares Outstanding, Beginning Balance Preferred stock shares outstanding Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding, Ending Balance Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Unrealized Gain Marketable securities Marketable Securities, Current Raw materials Inventory, Raw Materials, Gross Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of Stock-Based Compensation Expense Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock upon exercise of stock options Number of Options, Exercised Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued Expenses Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive loss (income) Other comprehensive income Proceeds from Sale and Maturity of Marketable Securities, Total Proceeds from Sale and Maturity of Marketable Securities Proceeds from maturities of marketable securities Subsequent Event Subsequent Event [Member] Accrued external research and development. Accrued External Research And Development Current External research and development Accrued external research and development Other Assets, Noncurrent, Total Other Assets, Noncurrent Other assets Antidilutive Securities [Axis] Antidilutive Securities Purchase Commitment, Excluding Long-Term Commitment [Axis] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract] Available-for-Sale Securities [Member] Available-for-Sale Securities AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income ALS Association and ALS Finding a Cure. A L S Association And A L S Finding Cure [Member] ALS Association and ALS Finding a Cure Preferred Stock, Value, Issued Preferred stock, $0.0001 par value; 10,000,000 shares authorized; 0 and 0 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively Selling, general and administrative Selling, General and Administrative Expense Selling, General and Administrative Expense, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Granted Financial Instrument [Axis] Financial Instrument Assets, Current [Abstract] Current assets: Segment Reporting [Abstract] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Liabilities, Current [Abstract] Current liabilities: Schedule of gross to net adjustments reserve. Schedule Of Gross To Net Adjustments Reserve [Table Text Block] Schedule of Activity and Ending Reserve Balance for GTN Adjustments Restricted Cash and Cash Equivalents, Total Restricted Cash and Cash Equivalent Restricted cash equivalents Commitments and Contingencies Commitments and contingencies (Note 9) Conversion of preferred stock into common stock upon initial public offering, Shares Conversion of preferred stock into common stock upon initial public offering, Shares Temporary equity shares conversion of preferred stock into common stock upon initial public offering. Temporary Equity Shares Conversion Of Preferred Stock Into Common Stock Upon Initial Public Offering Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Nonvested Weighted Average Grant Date Fair Value, Nonvested Work in process Inventory, Work in Process, Gross General and Administrative Expense [Member] General and Administrative Forecast [Member] Forecast Forecast Commitments and contingencies. Commitments And Contingencies [Table] Commitments And Contingencies [Table] Liability for Claims and Claims Adjustment Expense Liability for Claims and Claims Adjustment Expense, Ending Balance Liability for Claims and Claims Adjustment Expense, Beginning Balance Liability for Claims and Claims Adjustment Expense, Total Claims settlement amount Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net income (loss) Net (loss) income Net loss George Milne [Member] George Milne. George Milne Weighted Average Number of Shares Outstanding, Basic, Total Weighted-average shares used to compute basic net (loss) income per share Weighted-average shares used in computing net loss per share - basic Scenario [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Aggregate Intrinsic Value, Options exercisable Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Subsequent Events [Text Block] Subsequent Events APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense Equity, Attributable to Parent Ending Balance Beginning Balance Total stockholders' equity Payments to Acquire Investments, Total Payments to Acquire Investments Purchases of investments Preferred stock par value Preferred Stock, Par or Stated Value Per Share Basis of Presentation and Consolidation Basis of Accounting, Policy [Policy Text Block] Statement of Stockholders' Equity [Abstract] Cash Equivalents [Member] Cash equivalents Use of Estimates, Policy [Policy Text Block] Use of Estimates Entity Address, Address Line Two Fair Value Disclosures [Text Block] Fair Value Measurements Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued Expenses Total accrued expenses Accrued Liabilities and Other Liabilities Accrued expenses and other current liabilities Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Segment Reporting, Other Segment Item, Amount Other segment items Other assets Other assets Increase (Decrease) in Other Operating Assets Increase (Decrease) in Other Operating Assets, Total Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Rule 10b51 Arr Modified [Flag] Rule 10b51 Arr Modified. Rule 10b5-1 Arrangement Modified Debt Securities [Member] Marketable Securitites Settlement Liabilities, Current Settlement liability Entity Address, City or Town Entity Address, City or Town Accrued consulting and other professional fees Accrued Consulting And Other Professional Fess Accrued consulting and other professional fess. Agency bonds. Agency Bonds [Member] Agency Bonds Security Exchange Name Security Exchange Name Intersegment Eliminations [Member] Intersegment Eliminations [Member] Counterparty Name [Axis] Counterparty Name Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income taxes Antidilutive Securities, Name [Domain] Antidilutive Securities, Name Stockholders' Equity Note [Abstract] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Beginning Balance Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Ending Balance Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Total cash, cash equivalents and restricted cash equivalents: Statistical Measurement [Domain] Statistical Measurement Assets, Current Total current assets Stock-based compensation recognized Share-Based Payment Arrangement, Expense Total stock-based compensation expense Document Period End Date Document Period End Date Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Number of Options, Options exercisable Statement of Financial Position [Abstract] Common Stock Reserved for the Unvested Restricted Stock Units Restricted Stock Unit Restricted Stock Units Collateralized Debt Obligations [Member] Collateral for Letter of Credit Issued Product Revenue Revenue [Policy Text Block] Realized loss Debt Securities, Available-for-Sale, Realized Loss Antidilutive Security, Excluded EPS Calculation [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract] Reconciliation of cash, cash equivalents and restricted cash equivalents: Class of Stock [Axis] Class of Stock Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions Debt securities available-for-sale number of positions in an unrealized loss position Liabilities Total liabilities Gubra Agreement [Member] Gubra agreement. Gubra Agreement Financial Instruments [Domain] Dividends, Total Dividends Dividends paid Gross product revenue to net product revenue. Gross Product Revnue To Net Product Revenue [Table Text Block] Summary of Gross Product Revenue to Net Product Revenue Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions Debt securities available-for-sale in an unrealized loss position for greater than 12 months Weighted Average Number of Shares Outstanding, Diluted Weighted-average shares used to compute diluted net (loss) income per share Weighted-average shares used in computing net loss per share - diluted Securities Act File Number Entity File Number Cover [Abstract] Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Number of shares, Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Number of shares, Forfeited Investments [Domain] Investments Series C-2 Redeemable Convertible Preferred Stock Series C-2 redeemable convertible preferred shares. Series C2 Redeemable Convertible Preferred Shares [Member] Series C-2 Redeemable Convertible Preferred Shares Scenario [Domain] US Treasury Securities [Member] Treasury Bills Number of Operating Segments Number of operating segments Sale of Stock [Domain] Sale of Stock Segment Reporting Disclosure [Text Block] Segments Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Noncash Item [Abstract] Adjustments to reconcile net (loss) income to net cash provided by operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Subsequent Event [Table] Withholding taxes paid on stock-based awards. Withholding taxes paid on stock-based awards Withholding taxes paid on stock-based awards AMX0035 PSP [Member] AMX0035 PSP. AMX0035 - PSP Milestone payment for development candidate Milestone Payment For Development Candidate Milestone payment for development candidate. Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Ending Balance Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Beginning Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Weighted-Average Exercise Price, Options unvested New Accounting Pronouncements, Policy [Policy Text Block] New Accounting Pronouncements Not Yet Adopted Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Conversion of preferred stock into common stock upon initial public offering, Shares Conversion of preferred stock into common stock upon initial public offering, Shares Stock Issued During Period, Shares, Conversion of Convertible Securities Depreciation, Total Depreciation Depreciation expense Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc [Member] Eiger BioPharmaceuticals, Inc. Beginning Balance, Shares Ending Balance, Shares Common Stock, Shares, Outstanding Common stock, shares, outstanding Restricted Cash Equivalent, Noncurrent Restricted cash equivalents Operating lease liabilities, current portion Operating Lease, Liability, Current Operating lease right-of-use liabilities, current Document Transition Report Document Transition Report Research and Development Expense, Total Research and Development Expense Research and development Impairment charges Asset Impairment Charges Asset Impairment Charges, Total AMX0035 ALS [Member] AMX0035 ALS. AMX0035 - ALS Statement of Cash Flows [Abstract] Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, after Tax Other comprehensive income (loss) Stock Issued During Period, Value, New Issues Issuance of common stock upon initial public offering, net of issuance costs Issuance of common stock upon financing, net of issuance costs Share-Based Payment Arrangement, Option, Activity [Table Text Block] Summary of Stock Option Activity Stockholders' Equity Equity [Text Block] Earnings Per Share [Text Block] Net Loss Per Share Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Summary of Restricted Stock Unit Activity Net loss Net loss Net loss Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Outstanding Aggregate Intrinsic Value, Outstanding Inventory Write-down Inventory write-downs Inventory write-down James Frates [Member] James Frates. James Frates Available-for-sale investments contractual maturity period. Available For Sale Investments Contractual Maturity Period Available-for-sale investments contractual maturity period Assets [Abstract] Assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Document Fiscal Year Focus Document Fiscal Year Focus Purchase Commitment [Member] Purchase Commitments Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Cash flows provided by investing activities: Cash flows provided by (used in) investing activities: Other programs [Member] Other programs. Other programs Accounts Payable, Current, Total Accounts Payable, Current Accounts payable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Total fair value of stock options vested Research and Development Expense [Member] Research and Development Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Marketable Securities Milestone Payments Related To In Process Research And Development Milestone payments related to in process research and development. Milestone payments related to IPR&D Fair Value Disclosures [Abstract] Commitments and Contingencies Disclosure [Abstract] Share-Based Payment Arrangement [Abstract] Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Unrecognized Expense Nature Of The Information [Abstract] Nature of the information. Assets, Fair Value Disclosure Assets, Fair Value Disclosure, Total Assets measured at fair value Sale of Stock [Axis] Sale of Stock Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Net cash provided by (used in) investing activities Title of 12(b) Security Title of 12(b) Security Schedule of Segment Reporting Information, by Segment [Table] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted-Average Exercise Price, Cancelled or forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Forfeited Restricted cash. Restricted Cash [Member] Restricted cash Operating lease right-of-use assets. Increase Decrease In Operating Lease Right Of Use Assets Operating lease right-of-use assets Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted-Average Exercise Price, Outstanding Weighted-Average Exercise Price, Outstanding Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Additional Paid-in Capital [Member] Additional Paid-In Capital Measurement Frequency [Domain] Measurement Frequency Statement of Income Location, Balance [Axis] Income Statement Location Trading Symbol Trading Symbol Subsequent Event Type [Axis] Employee-related Liabilities, Current Employee-related Liabilities, Current, Total Accrued employee compensation and benefits Cash flows provided by financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Cash flows (used in) provided by financing activities: Fair Value, Recurring [Member] Fair Value Measurements, Recurring Entity Ex Transition Period Entity Ex Transition Period Series C-1 Redeemable Convertible Preferred Stock Series C-1 redeemable convertible preferred shares. Series C1 Redeemable Convertible Preferred Shares [Member] Series C-1 Redeemable Convertible Preferred Shares Equity Components [Axis] Equity Components Total direct research and development expenses by program Research and Development Expense (Excluding Acquired in Process Cost) Nonoperating Income (Expense) Total other income, net Equity Component [Domain] Equity Component Asset Class [Axis] Asset Class IPO [Member] Initial Public Offering Issuance of common stock upon vesting of rsus. Issuance Of Common Stock Upon Vesting Of Rsus Issuance of common stock upon vesting of RSUs US Treasury and Government [Member] Treasury notes Type of Borrower [Axis] Statement of Comprehensive Income [Abstract] Maximum [Member] Maximum Statistical Measurement Statistical Measurement [Axis] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted-Average Exercise Price, Exercised Common Stock, Value, Issued, Total Common stock, $0.0001 par value; 300,000,000 shares authorized; 68,079,057 and 67,707,432 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued Common stock, $0.0001 par value; 300,000,000 shares authorized; 111,026,477 and 109,884,502 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively Realized gains Debt Securities, Available-for-Sale, Realized Gain Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Net unrealized gain on available-for-sale securities Net unrealized loss on available-for-sale securities Other Nonoperating Income (Expense) [Abstract] Other income, net: Additional Amount Eligible To Receive Upon Achievement Of Certain Milestones Additional amount eligible to receive upon achievement of certain milestones. Additional amount eligible to receive upon achievement of certain milestones Preferred stock shares authorized Preferred Stock, Shares Authorized Total operating expenses Costs and Expenses Underlying Asset Class Underlying Asset Class [Axis] Revenue from Contract with Customer [Text Block] Product Revenue, Net Entity Registrant Name Entity Registrant Name Unrealized loss Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Unrealized Loss Other Nonoperating Income (Expense), Total Other Nonoperating Income (Expense) Other expense, net Subsequent Events [Abstract] Restricted cash equivalents. Restricted Cash equivalents [Member] Restricted Cash Equivalents Provision for income taxes (Benefit) provision for income taxes Income Tax Expense (Benefit) Income Tax Expense (Benefit), Total (Benefit) provision for income taxes Measurement Frequency Measurement Frequency [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Consolidation Items [Axis] Payments to Acquire Property, Plant, and Equipment, Total Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Class of Financing Receivable, Type of Borrower [Domain] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Number of shares, Granted Assets Total assets Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted- Average Remaining Contractual Term (in years), Options exercisable Alzheimers Drug Discovery Foundation, Alzheimers Association, and Cure Alzheimers Fund. Alzheimers Drug Discovery Foundation Alzheimers Association And Cure Alzheimers Fund [Member] Alzheimer's Drug Discovery Foundation, the Alzheimer's Association, and Cure Alzheimer's Fund Income Statement [Abstract] Selling, General and Administrative Selling, General and Administrative Expenses [Member] Stock Issued During Period, Shares, New Issues Issuance of common stock upon initial public offering, net of issuance costs, Shares Issuance of common stock upon financing, net of issuance costs, Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Number of shares, Vested Number of shares, Vested Proceeds from exercise of stock options and restricted stock units vesting. Proceeds From Exercise Of Stock Options And Restricted Stock Units Vesting Proceeds from exercise of stock options and RSUs vesting Earnings Per Share, Diluted, Total Earnings Per Share, Diluted Net loss per share - diluted Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of segment revenue and expenses to consolidated net loss Operating Segments [Member] Operating Segments [Member] Participants dose description Participants Dose Description Participants dose description. Purchase Commitment, Excluding Long-Term Commitment [Domain] City Area Code City Area Code Series B Redeemable Convertible Preferred Stock Series B redeemable convertible preferred shares. Series B Redeemable Convertible Preferred Shares [Member] Series B Redeemable Convertible Preferred Shares Counterparty Name [Domain] Counterparty Name Segment Reporting Information [Line Items] Issuance of common stock upon vesting of RSUs net of shares withheld for taxes. Issuance Of Common Stock Upon Vesting Of RSUs Net Of Shares Withheld For Taxes Issuance of common stock upon vesting of RSUs, net of shares withheld for taxes, Shares Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Total Property, Plant and Equipment, Net Property and equipment, net Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Cash, cash equivalents and restricted cash equivalents, beginning of period Cash, cash equivalents and restricted cash equivalents, end of period Loss from operations Operating Income (Loss) Loss from operations Retained Earnings [Member] Accumulated Deficit Share-based Payment Arrangement, Noncash Expense, Total Share-Based Payment Arrangement, Noncash Expense Stock-based compensation expense Issuance costs Payments of Stock Issuance Costs Operating Lease, Liability, Noncurrent Operating lease liabilities, net of current portion Fair Value, Inputs, Level 1 [Member] Level 1 Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Net cash provided by financing activities Asset Acquisition [Abstract] Cost of sales inventory impairment and loss on firm purchase commitments. Cost of sales inventory impairment and loss on firm purchase commitments Cost of sales - inventory impairment and loss on firm purchase commitments Inventory impairment and loss on firm purchase commitments Inventory impairment and loss on firm purchase commitments Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Antidilutive Shares Excluded from the Calculation of Diluted Net Loss Per Share Corporate Debt Securities Corporate Debt Securities [Member] Debt Securities, Available-for-Sale [Table] Entity Interactive Data Current Entity Interactive Data Current Statement of Income Location, Balance [Domain] Income Statement Location Cash flows (used in) provided by operating activities: Cash flows used in operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Asset Acquisition [Line Items] Accretion (Amortization) of Discounts and Premiums, Investments Accretion of investment discounts, net Raw material purchases and manufacturing services. Raw Material Purchases And Manufacturing Services [Member] Raw Material Purchases and Manufacturing Services Entity Tax Identification Number Entity Tax Identification Number Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Effect of exchange rate changes on cash, cash equivalents and restricted cash Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents Local Phone Number Local Phone Number Collateralized Credit Card Securities [Member] Collateral for Corporate Credit Card Program Royalty Agreement Terms [Member] Royalty Payments Agreements with Grantors Accounting Policies [Abstract] Debt securities available for sale number of positions. Debt securities available for sale number of positions Debt securities available-for-sale number of positions Class of Stock [Domain] Class of Stock Commercial Paper Commercial Paper [Member] Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted-average Recognition Period Entity Emerging Growth Company Entity Emerging Growth Company CO Chief Executive Officer [Member] CO chief executive officer.